Finding MYCure

Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "...

Full description

Saved in:
Bibliographic Details
Published inMolecular & cellular oncology Vol. 6; no. 5; p. e1618178
Main Authors Beaulieu, Marie-Eve, Soucek, Laura
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.01.2019
Taylor & Francis Group
Subjects
Author’s Views
mini-protein
MYC
NSCLC
OMOMYC
peptide therapeutic
NSCLC
MYC
OMOMYC
mini-protein
peptide therapeutic
Online AccessGet full text

Cover

More Information
Summary:Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered an impossible mission and several technical challenges have discouraged the development of MYC inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine "Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy", we demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo using an Omomyc-based mini-protein.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2372-3556
2372-3556
DOI:10.1080/23723556.2019.1618178